Sustained Improvement of Cystic Fibrosis Lung Disease following Initiation of Elexacaftor/Tezacaftor/Ivacaftor Therapy: Lessons from Real-World Studies

Am J Respir Crit Care Med. 2023 Nov 1;208(9):911-913. doi: 10.1164/rccm.202309-1646ED.

Authors

Eva Steinke^{1

2

3}, Mirjam Stahl^{1

2

3}

Affiliations

¹ Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Center Charité - Universitätsmedizin Berlin Berlin, Germany.
² Berlin Institute of Health at Charité - Universitätsmedizin Berlin Berlin, Germany.
³ German Center for Lung Research (DZL) Associated Partner Site Berlin, Germany.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Aminophenols / therapeutic use
Benzodioxoles / therapeutic use
Cystic Fibrosis* / drug therapy
Cystic Fibrosis* / genetics
Humans
Lung
Tomography, X-Ray Computed

Substances

elexacaftor
ivacaftor
tezacaftor
Aminophenols
Benzodioxoles